Premium
Loco‐regional treatment of hepatocellular carcinoma
Author(s) -
Lencioni Riccardo
Publication year - 2010
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.23725
Subject(s) - medicine , hepatocellular carcinoma , radiofrequency ablation , percutaneous ethanol injection , microwave ablation , irreversible electroporation , randomized controlled trial , percutaneous , clinical trial , radiology , ablation , oncology , lipiodol , surgery , electroporation , biochemistry , chemistry , gene
Loco‐regional treatments play a key role in the management of hepatocellular carcinoma (HCC). Image‐guided tumor ablation is recommended in patients with early‐stage HCC when surgical options are precluded. Radiofrequency ablation has shown superior anticancer effects and greater survival benefit with respect to the seminal percutaneous technique, ethanol injection, in meta‐analyses of randomized controlled trials, and is currently established as the standard method for local tumor treatment. Novel thermal and nonthermal techniques for tumor ablation—including microwave ablation, irreversible electroporation, and light‐activated drug therapy—seem to have potential to overcome the limitations of radiofrequency ablation and warrant further clinical investigation. Transcatheter arterial chemoembolization (TACE) is the standard of care for patients with asymptomatic, noninvasive multinodular tumors at the intermediate stage. The recent introduction of embolic microspheres that have the ability to release the drug in a controlled and sustained fashion has been shown to significantly increase safety and efficacy of TACE with respect to conventional, lipiodol‐based regimens. The available data for radioembolization with yttrium‐90 suggests that this is a potential new option for patients with HCC, which should be investigated in the setting of randomized controlled trials. Despite the advances and refinements in loco‐regional approaches, the long‐term survival outcomes of patients managed with interventional techniques are not fully satisfactory, mainly because of the high rates of tumor recurrence. The recent addition of molecular targeted drugs with antiangiogenic and antiproliferative properties to the therapeutic armamentarium for HCC has prompted the design of clinical trials aimed at investigating the synergies between loco‐regional and systemic treatments. The outcomes of these trials are eagerly awaited, because they have the potential to revolutionize the treatment of HCC. (H EPATOLOGY 2010;)